JB Chemicals & Pharmaceuticals Limited has responded to a clarification sought by the National Stock Exchange on its financial results for the financial year ended March 31, 2026. The exchange had sought clarification under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, regarding the results submitted on May 11, 2026.
In its reply dated May 21, 2026, JB Chemicals stated that the Board of Directors at its meeting held on May 11, 2026 approved the audited standalone and consolidated financial results for the year ended March 31, 2026. The exchange had emailed its query on May 20, 2026, and the company responded on May 21, 2026.
The meeting was held at the registered office in Mumbai and through video conferencing. The board approved the results for submission to the stock exchanges under the signature of Director Sudhir Menon, who was present in person at the meeting. Mr. Menon was authorized to sign the results on behalf of the board.
A certified true copy of the board resolution has been annexed with the clarification filing. The resolution authorized Mr. Menon to sign the audited financial results for submission to stock exchanges and to sign the extract of the results for publication in newspapers on behalf of the board.
The clarification was submitted to the National Stock Exchange of India Limited. The filing was signed by Sandeep Phadnis, Vice President - Secretarial and Company Secretary of JB Chemicals & Pharmaceuticals Limited.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.